Covid19
Conditions
Brief summary
Aim of the work Impact of serum vit D level in SLE patients with COVID-19 disease on severity of infection, duration of COVID-19 disease course, fatigue development as a complication for both SLE and COVID-19 and assess impact of prior chloroquine on COVID-19 disease outcomes Patients and methods 38 SLE patients previously diagnosed and on different lines of lupus management. Participants were presented to chest outpatient clinic and emergency hospital, Mansoura University with manifestation suggesting COVID-19 infection. Serum vit D was measured in serum by ELISA.
Detailed description
Primary objective: assess the impact of serum vit D level in SLE patients with COVID-19 disease on severity of infection and pandemic treatment outcome. Secondary objectives: * Effect of serum vit D level in SLE patients on duration of COVID-19 disease course and fatigue development as a complication for both SLE and COVID-19 * Impact of prior chloroquine on COVID-19 disease outcomes * Correlation of serum vit D level with different laboratory investigations at time of COVID-19 outbreak
Interventions
DRUGVitamin D
Impact of serum vit D level in SLE patients with COVID-19 disease on severity of infection, duration of COVID-19 disease course, fatigue development as a complication for both SLE and COVID-19 and assess impact of prior chloroquine on COVID-19 disease outcomes
DIAGNOSTIC_TESTELISA
Measure vitamin D level
Sponsors
Mansoura University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* \- SLE patients previously diagnosed * Patients are not suffering from malignancies. * Patients have no organ failure nor uncontrolled medical illness. * Recent COVID-19 infection
Exclusion criteria
* \- Pregnant, lactating females * Concurrent malignancies * Patients with other autoimmune disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Level of serum vitamin D in SLE infected with COVID-19 | 6 months | Measurement of serum vit D level (ng/ml) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Vitamin D level with COVID-19 severity | 6 months | Level of serum vitamin D (ng/ml) in mild, moderate and sever COVID-19 |
Other
| Measure | Time frame | Description |
|---|---|---|
| Impact of serum vit D level in SLE patients on duration of COVID-19 disease course | 6 months | serum vit D level (ng/ml) in SLE patients and time to recovery (number of days) from COVID-19 |
| Impact of prior chloroquine on COVID-19 disease outcomes | 6 months | Can prior chloroquine in SLE patients affect outcome of COVID-19 infection (recovery or die) |
| Serum vitamin D level and development of fatigue | 6 months | Basal vitamin d level (ng/ml) in SLE patients diagnosed with recent COVID-19 and development of fatigue after recovery from COVID-19 infection |
| Correlation of serum vit D level with different laboratory investigations at time of COVID-19 outbreak | 6 months | Correlation of serum vit D level (ng/ml) with ESR, CRP, serum Lymphocyte count, Ferritine, D-dimer at time of COVID-19 diagnosis |
Countries
Egypt
Outcome results
None listed